Pak M, Lopez MA, Gabayan V, et al. Suppression of hepcidin during
anemia requires erythropoietic activity. Blood 2006; 108:
Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone
as an erythroid regulator of iron metabolism. Nat Genet. 2014; 46:
Arezes J, Foy N, McHugh K, et al. Erythroferrone inhibits the
induction of hepcidin by BMP6. Blood 2018; 132: 1473–1477.
Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and
urinary hepcidin in β-thalassemia. Haematologica 2007; 92:
Gaudio A, Morabito N, Catalano A, et al. Pathogenesis of thalassemia
major-associated osteoporosis: A review with insights from clinical experience.
J Clin Res Pediatr Endocrinol. 2019; 11: 110–117.
Datzmann T, Trautmann F, Tesch F, et al. Associations of myeloid
hematological diseases of the elderly with osteoporosis: A longitudinal analysis
of routine health care data. Leuk Res. 2018; 69: 81–86.
Karner CM, Lee S-Y, Long F. BMP induces osteoblast differentiation
through both Smad4 and mTORC signaling. Mol Cell Biol. 2017; 37: .
Spoto B, Kakkar R, Lo L, et al. Serum erythroferrone levels
associate with mortality and cardiovascular events in hemodialysis and in CKD
patients: A two cohorts study. J Clin Med. 2019; 8: 523. 10.3390/jcm8040523.)| false